Strategic raw material selection for cell therapy commercialization
s
Nov
9
2023
On demand

Strategic raw material selection for cell therapy commercialization

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Strategic raw material selection for cell therapy commercialization

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In the ever-evolving global landscape of cell therapy development, selecting quality raw materials is crucial for achieving clinical and commercial milestones. In this webinar, industry leaders will share insights into the key factors influencing raw material selection throughout different phases of development.

  • Important factors for critical raw materials selection:
  • Catering to both early and late-phase requirements to ensure seamless transitions
  • Expedited drug development and challenges presented to the industry
  • Top considerations when evaluating a raw materials supplier
  • Navigating global regulatory complexities through documentation and vendor support
Kasey Kime
Kasey Kime
Director, Regulatory Affairs – Cell, Gene, & Advanced Therapies at Thermo Fisher Scientific

With over fifteen years of experience, Kasey Kime is a seasoned professional in global quality and regulatory affairs within the Life Sciences sector. She presently holds the role of Director of Regulatory Affairs at Thermo Fisher Scientific, where her focus is centered on technology and tools essential for cell and gene therapy manufacturing. Kasey's specific interests lie in areas such as CMC (Chemistry, Manufacturing, and Controls), advanced manufacturing, and companion diagnostics. Her education comprises a bachelor’s degree in medical laboratory science, complemented by post-graduate degrees in Medical Microbiology, Quality Systems Management, and Business Administration. Beyond her role at Thermo Fisher Scientific, Kasey remains actively engaged by contributing to the industry, notably through her roles in the Australia and New Zealand ISCT Regulatory Committee and the Alliance for Regenerative Medicine (ARM) CMC Advisory Group.

Lili Belcastro
Lili Belcastro
Senior Principal Scientist at Bristol-Myers Squibb

Dr Lili Belcastro is a Senior Principal Scientist at Bristol-Myers Squibb. She leads the Material Sciences group in Cell Therapy Development. Lili has over fifteen years of experience in preclinical and clinical cancer biology, cell and gene therapy product development, and method development working with a variety of complex biological molecules, small molecule inhibitors, ancillary materials, starting materials, and gene editing materials. Lili holds a PhD in cancer biology from a joint program with the University of the Sciences and The Wistar Institute in Philadelphia.

Kyle Hondorp
Kyle Hondorp
Senior Manager, Product Management, Cell and Gene Therapy at Thermo Fisher Scientific
Kyle Hondorp is a Senior Manager, Product Management for the Cell and Gene Therapy at Thermo Fisher Scientific where she is responsible for managing the Gibco™ Cell Therapy Systems (CTS™) immunotherapy and adult stem cell culture media and reagents. Kyle initially joined Thermo Fisher Scientific in 2018 as Product Manager for the Applied Biosystems™ PCR plastics and thermal cycler portfolio after spending 18 years working for Active Motif, a life sciences company focused on providing solutions for epigenetic research. Kyle earned her Bachelor of Science in Genetics at the University of California, Davis and Master of Business Administration at California State University, San Marcos.